Hangzhou Innogate Pharma Co. Ltd. has reported cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors. They are described as useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, multiple sclerosis, myocardial infarction and Parkinson’s disease, among others.
Chong Kun Dang Pharmaceutical Corp. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors designed for use in the treatment of cancer and inflammatory disorders.
Driven by prescription drug prices and oft-repeated claims that nearly every drug developed in the U.S. owes its origins to taxpayer-funded research, watchdog groups and some lawmakers have led demands over the years for price to be considered a “reasonableness” factor in determining whether the government can march in on patents under the Bayh-Dole Act.
Shanghai SIMR Biotech Co. Ltd. has prepared and tested new GABA-A receptor subunit α5 (GABRA5) inverse agonists. They are reported to be useful for the treatment of pain, stroke and Alzheimer’s disease.
Tarapeutics Science Inc. has reported new pyrazolopyridine compounds acting as dual specificity protein kinase CLK and dual specificity tyrosine-phosphorylation-regulated kinase (DYRK) inhibitors.
East China Normal University and Fudan University have jointly discovered tricyclic pyrimidine compounds acting as adenosine A2A and/or A2B receptor antagonists.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
Shenzhen Targetrx Inc. has designed new proteolysis targeting chimeric (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to an EGFR L858R-, L858R/T790M double mutant- and L858R/T790M/C797S triple mutant-targeting moiety through a linker reported to useful for the treatment of non-small-cell lung cancer.
RSS
